A recent study assessed cholesterol efflux capacity of CSF by analyzing AD patients, non-AD patients, and control subjects.156 The results demonstrated that ABCA1-mediated CSF-cholesterol efflux capacity was markedly reduced in AD but not in non-AD demented patients. The gene discussed is ABCA1; the disease is Alzheimer disease.